

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number
WO 2004/098579 A2

- (51) International Patent Classification⁷: **A61K 31/00**
- (21) International Application Number:
PCT/GB2004/001926
- (22) International Filing Date: 4 May 2004 (04.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0310881.8 12 May 2003 (12.05.2003) GB
- (71) Applicant (*for all designated States except US*): **MERCK SHARP & DOHME LIMITED** [GB/GB]; Hertford Road, Hoddesdon Hertfordshire EN11 9BU (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **CASTRO PINEIRO, Jose, Luis** [ES/GB]; Terlings Park, Eastwick Road, Harlow Essex CM20 2QR (GB).
- (74) Agent: **HORGAN, James, Michael, Frederic**; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION OF A GLYCINE/NMDA ANTAGONIST AND A TACHYKININ NK-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF NEURODEGENERATION

(57) Abstract: The present invention relates to a pharmaceutical formulation comprising a compound which is active as an antagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor in combination with a tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral ischemia.

WO 2004/098579 A2

JG20 Rec'd PCT/PTO 02 NOV 2005

COMBINATION OF A GLYCINE/NMDA ANTAGONIST AND A
TACHYKININ NK-1 RECEPTOR ANTAGONIST FOR USE IN THE
TREATMENT OF NEURODEGENERATION

5 The present invention relates to a pharmaceutical composition comprising a combination of active ingredients. More particularly, the invention concerns a pharmaceutical formulation comprising a compound which is active as an antagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor (hereinafter referred to as a "glycine/NMDA antagonist") in combination with a
10 tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral ischemia.

 Glycine/NMDA antagonists are well known from the art to be of benefit in the treatment of acute neurodegenerative disorders arising from
15 events such as stroke, transient ischemic attack, peri-operative ischemia, global ischemia (following cardiac arrest), and traumatic head injury to the brain or spinal cord. In addition, glycine/NMDA antagonists may be of use in treating certain chronic neurological disorders such as senile dementia, Parkinson's disease and Alzheimer's disease. They may also
20 have utility in conditions in which peripheral nerve function has been impaired, such as retinal and macular degeneration.

 Glycine/NMDA antagonists have, moreover, been reported as being beneficial in treating epilepsy; anxiety; substance abuse and/or addiction, e.g. alcoholism; pain; hearing disorders, e.g. tinnitus; migraine; and
25 psychiatric disorders such as schizophrenia. However, mechanism-based side effects, principally including nausea and vomiting, have been reported following administration of certain glycine/NMDA antagonists during clinical trials.

 The neuropeptide receptors for substance P (SP; neurokinin-1; NK-
30 1) are widely distributed throughout the mammalian nervous system (especially the brain and spinal ganglia), circulatory system and

peripheral tissues (especially the duodenum and jejunum), and are involved in regulating a variety of diverse biological processes. These include the sensory perception of olfaction, vision, audition and pain; movement control; gastric motility; vasodilation; salivation; and
5 micturition.

Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. In addition to SP, the known mammalian tachykinins include neurokinin A
10 and neurokinin B. The current nomenclature designates the receptors for substance P, neurokinin A and neurokinin B as neurokinin-1, neurokinin-2 and neurokinin-3 respectively.

Tachykinin neurokinin-1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological
15 disorders associated with an excess or imbalance of tachykinins, in particular SP. Examples of such conditions include disorders of the central nervous system including anxiety, depression and psychosis. Recently, the tachykinin NK-1 receptor antagonist aprepitant [2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-
20 oxo-1H,4H-1,2,4-triazolo)methyl)morpholine] has been approved by the US Food and Drug Administration (FDA) for use in preventing the acute and delayed nausea and vomiting associated with cancer chemotherapeutic agents, including high-dose cisplatin.

It has now been found that the co-administration of a
25 glycine/NMDA antagonist in conjunction with a tachykinin NK-1 receptor antagonist provides beneficial results in the treatment of neurodegeneration arising, in particular, from stroke or cerebral ischemia.

The present invention accordingly provides a method for the treatment of neurodegeneration which comprises administering to a
30 patient in need of such treatment, either simultaneously, separately or

sequentially, a combination of a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist.


The present invention also provides the use of a combination of a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist for
5 the manufacture of a medicament for the treatment of neurodegeneration.

In another aspect, the present invention provides a pharmaceutical composition comprising a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist in association with a pharmaceutically acceptable carrier.


10 In a further aspect, the present invention provides a product containing a glycine/NMDA antagonist and a tachykinin NK-1 receptor antagonist as a combined preparation for simultaneous, separate or sequential use in the treatment of neurodegeneration.

In the normal practice of the invention, the glycine/NMDA
15 antagonist and the tachykinin NK-1 receptor antagonist will usually be administered to a patient within a reasonable period of time, which will typically be up to about one hour apart. The compounds may be in the same pharmaceutical carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers and administered
20 simultaneously, by mixing the materials just prior to administration. They may alternatively be in different dosage forms which can be taken simultaneously, or administered sequentially.

Typical glycine/NMDA antagonists of use in the present invention are, for example, described in EP-A-0481676. Preferred glycine/NMDA
25 antagonists of use in this invention include UK-240,455 and UK-333,747, disclosed in WO 96/09295 [Example 80(d)] and WO 98/38186 (derived from WO 97/32873) respectively, the chemical structures of which are as follows:



UK-240,455



UK-333,747

The tachykinin NK-1 receptor antagonists of use in the present invention may be peptidal or non-peptidal in nature. However, the use of a non-peptidal tachykinin NK-1 receptor antagonist is preferred. In a preferred embodiment, the tachykinin NK-1 receptor antagonist is a CNS-penetrant tachykinin NK-1 receptor antagonist. In addition, for convenience the use of an orally active tachykinin NK-1 receptor antagonist is preferred. To facilitate dosing, it is also preferred that the tachykinin NK-1 receptor antagonist is a long acting tachykinin NK-1 receptor antagonist. An especially preferred class of tachykinin NK-1 receptor antagonists of use in the present invention comprises those compounds which are both orally active and long acting.

Tachykinin NK-1 receptor antagonists of use in the present invention are fully described, for example, in U.S. Patent Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595, 5,459,270, 5,494,926, 5,496,833 and 5,637,699; European Patent Publication Nos. EP 0 360 390, 0 394 989, 0 428 434, 0 429 366, 0 430 771, 0 436 334, 0 443 132, 0 482 539, 0 498 069, 0 499 313, 0 512 901, 0 512 902, 0 514 273, 0 514 274, 0 514 275, 0

514 276, 0 515 681, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456,
0 533 280, 0 536 817, 0 545 478, 0 558 156, 0 577 394, 0 585 913, 0 590
152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535,
0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 709 375, 0 709 376,
5 0 714 891, 0 723 959, 0 733 632 and 0 776 893; PCT International Patent
Publication Nos. WO 90/05525, 90/05729, 91/09844, 91/18899, 92/01688,
92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677,
92/22569, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170,
93/06099, 93/09116, 93/10073, 93/14084, 93/14113, 93/18023, 93/19064,
10 93/21155, 93/21181, 93/23380, 93/24465, 94/00440, 94/01402, 94/02461,
94/02595, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843,
94/08997, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639,
94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735,
94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886,
15 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/17382,
95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 95/22525, 95/23798,
95/26338, 95/28418, 95/30674, 95/30687, 95/33744, 96/05181, 96/05193,
96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197,
96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385,
20 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362,
97/18206, 97/19084, 97/19942, 97/21702 and 97/49710; and British Patent
Publication Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774,
2 292 144, 2 293 168, 2 293 169 and 2 302 689.

A preferred tachykinin NK-1 receptor antagonist of use in the
25 present invention is aprepitant (*supra*), disclosed in WO 95/16679.

In a preferred embodiment of the present invention, UK-240,455 or
UK 333,747 may be co-administered, as described herein, with aprepitant.

The pharmaceutical composition according to the present invention
may conveniently be adapted for administration orally, rectally or
30 parenterally. For oral administration, the formulation may be presented
in the form of tablets, pills, capsules, powders or granules; for parenteral

administration, sterile parenteral solutions or suspensions may conveniently be utilised; and for rectal administration, the formulation may conveniently be in the form of suppositories. Suitably, the pharmaceutical compositions in accordance with the invention may be presented in the form of a kit of parts adapted for simultaneous, separate or sequential administration.

The compositions may be formulated by conventional methods well known in the pharmaceutical art, for example as described in *Remington: The Science and Practice of Pharmacy*, Mack Publishing Company, 19th Edition, 1995.

For administration in combination, the glycine/NMDA antagonist and the tachykinin NK-1 receptor antagonist may be presented in a ratio which is consistent with the manifestation of the desired effect. In particular, the molar ratio of the glycine/NMDA antagonist to the tachykinin NK-1 receptor antagonist will suitably be approximately 1 to 1. Preferably, this ratio will be between 0.001 to 1 and 1000 to 1, and especially from 0.01:1 to 100:1.

For co-administration with a tachykinin NK-1 receptor antagonist in the treatment of neurodegeneration, the glycine/NMDA antagonist may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg, and especially about 0.05 to 10 mg/kg. For co-administration with a glycine/NMDA antagonist in the treatment of neurodegeneration, the tachykinin NK-1 receptor antagonist may suitably be administered at a daily dosage of about 0.001 to 250 mg/kg, typically about 0.005 to 100 mg/kg, more particularly about 0.01 to 50 mg/kg and especially about 0.05 to 10 mg/kg. The active ingredients will typically be co-administered on a regimen of 1 to 4 times per day.

The following non-limiting Examples serve to illustrate the present invention.

EXAMPLES 1 TO 4Tablet Preparation

Tablets containing UK-240,455 and aprepitant, or UK-333,747 and
5 aprepitant, were prepared as follows:

	<u>Example 1</u>	<u>Example 2</u>
UK-240,455	5.0 mg	10.0 mg
Aprepitant	10.0 mg	10.0 mg
Microcrystalline cellulose	42.0 mg	39.5 mg
Modified food corn starch	42.0 mg	39.5 mg
Magnesium stearate	1.0 mg	1.0 mg


	<u>Example 3</u>	<u>Example 4</u>
UK-333,747	5.0 mg	10.0 mg
Aprepitant	10.0 mg	10.0 mg
Microcrystalline cellulose	42.0 mg	39.5 mg
Modified food corn starch	42.0 mg	39.5 mg
Magnesium stearate	1.0 mg	1.0 mg

10 All of the active ingredients, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and magnesium stearate. The resulting granulation is then compressed into tablets.

CLAIMS


1. A combination of a glycine/NMDA antagonist and a tachykinin
NK-1 receptor antagonist for simultaneous, separate or sequential use in
5 the treatment of neurodegeneration.

2. A combination as defined in claim 1 wherein the glycine/NMDA
antagonist is:



UK-240,455

or



UK-333,747.

10

3. A combination as defined in claim 2 wherein the glycine/NMDA
antagonist is UK-240,455.

15 4. A combination as defined in claim 2 wherein the glycine/NMDA
antagonist is UK-333,747.

5. A combination as defined in any previous claim wherein the tachykinin NK-1 receptor antagonist is aprepitant [2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine].
- 5
6. A pharmaceutical composition comprising a combination as defined in any previous claim in association with a pharmaceutically acceptable carrier.
- 10 7. The use of a combination as defined in any one of claims 1 to 5 for the manufacture of a medicament for the treatment of neurodegeneration.
8. A method for the treatment of neurodegeneration which comprises administering to a patient in need of such treatment a combination as
- 15 defined in claim 1.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 November 2004 (18.11.2004)

PCT

(10) International Publication Number
WO 2004/098579 A3

(51) International Patent Classification⁷: **A61K 31/498**,
31/5377, A61P 25/00

(21) International Application Number:
PCT/GB2004/001926

(22) International Filing Date: 4 May 2004 (04.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0310881.8 12 May 2003 (12.05.2003) GB

(71) Applicant (for all designated States except US): **MERCK
SHARP & DOHME LIMITED** [GB/GB]; Hertford Road,
Hoddesdon Hertfordshire EN11 9BU (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CASTRO PINEIRO,**
Jose, Luis [ES/GB]; Terlings Park, Eastwick Road, Harlow
Essex CM20 2QR (GB).

(74) Agent: **HORGAN, James, Michael, Frederic**; Terlings
Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
27 January 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION OF A GLYCINE/NMDA ANTAGONIST AND A TACHYKININ NK-1 RECEPTOR ANTAGONIST
FOR USE IN THE TREATMENT OF NEURODEGENERATION

(57) Abstract: The present invention relates to a pharmaceutical formulation comprising a compound which is active as an an-
tagonist of the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor in combination with
a tachykinin NK-1 receptor antagonist, for use in the treatment of neurodegeneration arising, in particular, from stroke or cerebral
ischemia.

WO 2004/098579 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/001926

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/498 A61K31/5377 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96/09295 A (FRAY MICHAEL JONATHAN ; STOBIE ALAN (GB); PFIZER LTD (GB); MOWBRAY CHA) 28 March 1996 (1996-03-28) cited in the application claims 1-15	1-8
Y	WO 98/38186 A (WAITE DAVID CHARLES ; STOBIE ALAN (GB); PFIZER LTD (GB); CROOK ROBERT) 3 September 1998 (1998-09-03) cited in the application claims 1-11 page 11, line 6 - line 29	1-8
Y	WO 95/16679 A (LADDUWAHETTY TAMARA ; WILLIAMS BRIAN JOHN (GB); CHAMBERS MARK STUART) 22 June 1995 (1995-06-22) cited in the application claims 1,15-20	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

25 October 2004

Date of mailing of the international search report

03/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/001926

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No.

PCT/GB2004/001926

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9609295	A	28-03-1996	AT 213731 T	15-03-2002
			AU 688591 B2	12-03-1998
			AU 3523295 A	09-04-1996
			BR 9504132 A	06-08-1996
			CA 2200742 A1	28-03-1996
			CN 1158610 A	03-09-1997
			CZ 9700857 A3	16-09-1998
			DE 69525633 D1	04-04-2002
			DE 69525633 T2	08-08-2002
			DK 783495 T3	22-04-2002
			WO 9609295 A1	28-03-1996
			EP 0783495 A1	16-07-1997
			ES 2171553 T3	16-09-2002
			FI 971193 A	21-05-1997
			HU 77734 A2	28-07-1998
			JP 2986920 B2	06-12-1999
			JP 9511526 T	18-11-1997
			NO 971261 A	05-05-1997
			NZ 292922 A	28-07-1998
			PL 319405 A1	04-08-1997
			PT 783495 T	31-07-2002
			RU 2135484 C1	27-08-1999
			TR 970064 A2	21-02-1997
			US 5852016 A	22-12-1998
			ZA 9508023 A	24-03-1997
WO 9838186	A	03-09-1998	AP 767 A	29-09-1999
			AT 208773 T	15-11-2001
			AU 717972 B2	06-04-2000
			AU 2023197 A	22-09-1997
			AU 723467 B2	24-08-2000
			AU 6827998 A	18-09-1998
			BG 63340 B1	31-10-2001
			BG 102760 A	30-09-1999
			BG 103685 A	30-06-2000
			BR 9707851 A	27-07-1999
			BR 9808126 A	08-03-2000
			CA 2248366 A1	12-09-1997
			CA 2281580 A1	03-09-1998
			CN 1443763 A	24-09-2003
			CN 1121403 B	17-09-2003
			DE 69708269 D1	20-12-2001
			DE 69708269 T2	25-07-2002
			DK 885212 T3	25-03-2002
			EA 1730 B1	27-08-2001
			EA 1658 B1	25-06-2001
			WO 9838186 A1	03-09-1998
			EP 0885212 A1	23-12-1998
			EP 0973766 A1	26-01-2000
			HK 1025317 A1	02-01-2004
			HR 980104 A1	28-02-1999
			HU 0003612 A2	28-10-2001
			IL 125491 A	06-07-2003
			JP 3110467 B2	20-11-2000
			JP 11506123 T	02-06-1999
			JP 2000509730 T	02-08-2000
			JP 2004269547 A	30-09-2004
			NO 984058 A	06-11-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/001926

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9838186	A	NO 994135 A	22-10-1999
		NZ 331060 A	28-01-2000
		NZ 336842 A	26-05-2000
		OA 11189 A	14-05-2003
		PL 329032 A1	01-03-1999
		PL 335501 A1	25-04-2000
		SI 885212 T1	28-02-2002
		SK 113399 A3	09-04-2001
		SK 121498 A3	09-10-2000
		TR 9902055 T2	21-07-2000
		US 6376490 B1	23-04-2002
		US 6333326 B1	25-12-2001
		ZA 9801603 A	26-08-1999
		AP 982 A	16-07-2001
WO 9516679	A	22-06-1995	
		AT 194336 T	15-07-2000
		AU 701862 B2	04-02-1999
		AU 1437595 A	03-07-1995
		BG 100715 A	31-01-1997
		BR 9408351 A	26-08-1997
		CA 2178949 A1	22-06-1995
		CN 1142819 A ,B	12-02-1997
		CY 2203 A	08-11-2002
		CZ 9601772 A3	11-12-1996
		DE 69425161 D1	10-08-2000
		DE 69425161 T2	15-02-2001
		DK 734381 T3	18-09-2000
		EP 0734381 A1	02-10-1996
		ES 2147840 T3	01-10-2000
		FI 962489 A	13-08-1996
		GR 3034095 T3	30-11-2000
		HK 1009046 A1	11-05-2001
		HR 941000 A1	30-06-1997
		HU 76476 A2	29-09-1997
		IL 111960 A	22-12-1999
		JP 9506628 T	30-06-1997
		JP 3245424 B2	15-01-2002
		LU 91069 A9	07-04-2004
		LV 11617 A ,B	20-12-1996
		NL 300146 I1	01-06-2004
		NO 962523 A	16-08-1996
		NZ 278222 A	27-05-1998
		PL 315153 A1	14-10-1996
		PT 734381 T	29-12-2000
		RO 118203 B1	28-03-2003
		RU 2201924 C2	10-04-2003
		SI 734381 T1	31-10-2000
		SK 75396 A3	04-12-1996
		TW 419471 B	21-01-2001
		WO 9516679 A1	22-06-1995
		US 5637699 A	10-06-1997
		US 5719147 A	17-02-1998
		US 6235735 B1	22-05-2001
		US 2002002164 A1	03-01-2002
		US 5872116 A	16-02-1999
		US 5922706 A	13-07-1999
		ZA 9410008 A	15-07-1996